Novartis (ADR) (NVS)
Develops innovative medicines across four therapeutic areas and multiple advanced technology platforms.
Something off on this page? Send us feedback.
Develops innovative medicines for cardiovascular-renal-metabolic disease, immunology, neuroscience and oncology using established biologics and chemistry alongside gene and cell, radioligand and xRNA platforms. A decade of separations left innovative medicines as the sole operating focus, with products sold across approximately 120 countries.
Develops and markets innovative medicines across cardiovascular-renal-metabolic disease, immunology, neuroscience and oncology. Its science base combines chemistry and biotherapeutics with gene and cell therapy, radioligand therapy and xRNA platforms.
Products are sold across approximately 120 countries from a Basel headquarters. The operating portfolio was narrowed through the Alcon separation and Sandoz spin-off, leaving innovative medicines as the sole focus; targeted acquisitions add selected therapeutic assets and technology platforms.
Execution centers on a unified research organization and continued portfolio reshaping. The business depends on successful drug development, regulatory approvals, patent protection, and reliable clinical and product-testing data, while promotion and payment practices remain subject to compliance controls.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Upgrade | Target: $112 | Target: $136 |
| Sep 9, 2026 | HSBC | Upgrade | ||
| Sep 8, 2026 | Deutsche Bank | Downgrade | ||
| Sep 8, 2026 | RBC Capital | Initiate | Rating: — | |
| Mar 26, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $143 | Target: $170 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.69B · Total debt $49.01B · Total assets $122.03B · Shareholders' equity $41.54B
- Revenue
- $14.42B
- Operating income
- $4.74B
- Net income
- $3.27B
HistoryDividendAnnual yield
| Institutions | 7.14% | 136.17M ADS | |
|---|---|---|---|
| 1,672 holders · as of Jun 30, 2026 | |||
| Strategic holders | 7.32% | 139.60M ADS | |
| 1 holder · as of Jul 17, 2025 | |||
| Other | 85.54% | 1.63B ADS | |
| remainder | |||
1.91B ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCStrategic | 7.32% | 139.60M | filed Jul 17, 2025 |
Fisher Asset Management, LLCInstitution | 0.81% | 15.52M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.46% | 8.73M ADS | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 0.43% | 8.12M ADS | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 0.35% | 6.59M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- AstraZeneca (ADR)
Broad rival across oncology, PNH and respiratory immunology
- Eli Lilly
Direct rival in breast cancer and IL-17 immunology markets
- AbbVie
Major immunology rival across psoriatic and axial diseases
- Merck
Oncology rival in melanoma and non-small cell lung cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Novartis (ADR) | $140.40 | −0.41% | $267.96B | 21.3 | 14.9 | 4.8 | +0.9% |
| AstraZeneca (ADR) | $167.17 | −0.55% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| Eli Lilly | $1,141.01 | −2.05% | $1.10T | 39.1 | 27.9 | 13.8 | +47.7% |
| AbbVie | $262.58 | −0.72% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Merck | $148.57 | −0.62% | $369.24B | 119.6 | 17.2 | 5.6 | +5.1% |
| Median | 56.8 | 17.2 | 6.4 | +8.3% |